Eptifibatide

Brand (proprietary) name

None — marketed under its generic name

Generic (nonproprietary) name

eptifibatide

Active ingredient(s)

eptifibatide

Strength(s)

.75 mg/mL; 2 mg/mL; 20 mg/10mL; 200 mg/100mL; 75 mg/100mL

Dosage form(s)

Injection; Injection, Solution

Route(s)

Intravenous

Manufacturer / labeler

Baxter Healthcare CorporationAccord Healthcare Inc.AkornSagent PharmaceuticalsHainan Shuangcheng Pharmaceuticals Co., Ltd.Eugia US LLCMylan Institutional LLCAmneal Pharmaceuticals LLCSlate Run Pharmaceuticals, LLCAthenex Pharmaceutical Division, LLC.Meitheal Pharmaceuticals Inc.Avenacy, LLC

Product class

Generic (ANDA) (derived from FDA marketing category)

Marketing category

ANDA

Application number(s)

ANDA203258, ANDA204589, ANDA204693, ANDA205557, ANDA205581, ANDA206127, ANDA208554, ANDA209864, ANDA213081, ANDA213599

Earliest marketing start

Dec 8, 2015

Products / packages indexed

30 / 32

FDA pharmacologic class: Decreased Platelet Aggregation [PE]; Platelet Aggregation Inhibitor [EPC]

Also searchable as: eptifibatide

Prescribing information on DailyMed (NLM)

• J1327JJ-code: Drugs administered other than oral method; chemotherapy drugsActiveDerived calculation

  Injection, eptifibatide, 5 mg

  Derived: 29 of 32 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J1327. CMS quarters Q1 2022 – Q4 2026

  J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.

No authoritative public data was located for this field.

Home infusion per diem (S-codes)

Medicare

Not payable by Medicare — CMS coverage code I (all 2 codes)

Part B pricing indicator

00 — Not separately priced by Part B (all 2 codes)

National payment amount

Other drugs crosswalked to the same code(s)

• Integrilin · J1327

Which Medicare benefit pays for this drug?

• Coverage documents for eptifibatide NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “eptifibatide”. Covered diagnosis codes are listed in the articles.
• Coverage documents for J1327 NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “J1327”. Covered diagnosis codes are listed in the articles.

No current Medicare Billing and Coding article lists J1327.

• FDA NDC Directory data is submitted by labelers; FDA notes that inclusion does not mean the information was verified or that a product is approved, covered, or reimbursable.
• HCPCS links are derived from CMS NDC–HCPCS crosswalks, which support ASP-based Part B payment and are not a complete list of billable NDCs.
• Product class (brand, generic, biosimilar) is derived from the FDA marketing category and Purple Book license type, not from a commercial compendium.
• Payment limits are Medicare Part B national limits; they do not reflect payer contracts, OPPS rates, 340B pricing, or acquisition cost.
• Home infusion per diem S-codes are matched by therapy category from the FDA pharmacologic class and route, not from a CMS crosswalk. Payers choose which per diem codes they accept, and the right code can depend on the dosing schedule, infusion method, or daily volume.